An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn how Intravenous Immune Globulin (IVIG) will affect
Spinocerebellar Ataxia (SCA) symptoms and how it will affect motor and nervous system
function in participants Subtypes of SCA to be examined will include SCA types 1, 2, 3, 6, 10
and 11.